This is a working overview of LC-MS, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-08-01. Anything still debated is marked as such rather than presented as settled.
Dihexa is a synthetic peptide-like compound studied in preclinical research for its reported effects on synaptic growth and cognitive measures in animal models. It is often described as an analog of angiotensin IV, a naturally occurring peptide fragment. The compound has not been approved as a medicine in any major jurisdiction. Most public information comes from laboratory studies, patents, and online vendor listings rather than from large clinical trials. Its scientific status therefore differs from that of an established pharmaceutical.
Research interest in dihexa centers on its ability to promote synapse formation in cultured neurons and in some rodent experiments. These findings have been interpreted as a possible mechanism for learning and memory effects, but the evidence remains preliminary. Independent replication is limited, and study designs vary widely in species, duration, and outcome measures. Human data are scarce, so claims about cognitive enhancement in people are not supported by robust clinical evidence. The gap between laboratory signals and proven clinical benefit is substantial.
Dihexa appears in scientific literature, patent documents, and commercial catalogs under several names, which can complicate searching and verification. The compound is frequently grouped with nootropics or research chemicals, terms that describe context of use rather than regulatory approval. Such labeling may imply benefits that have not been confirmed in controlled human studies. Readers encountering promotional descriptions should distinguish between preclinical observations and established medical facts. The absence of regulatory approval is a central feature of its current status.
Research on dihexa has primarily used rodent models and cultured cells. Common endpoints include dendritic spine density, synaptic protein expression, and performance on maze or avoidance tasks. Some studies report improvements in cognitive measures after scopolamine-induced deficits or in aged animals. These findings are interesting but come from a small body of work, and independent laboratories have not consistently replicated all reported effects. Larger, preregistered studies would help clarify which results are robust.
Human data for dihexa remain absent from peer-reviewed clinical literature. As a result, questions about absorption, distribution, metabolism, excretion, and long-term safety are unresolved. Discussions often appear in nootropic forums, where anecdotal reports cannot substitute for controlled trials. Researchers have called for more rigorous pharmacokinetic and toxicological studies before any clinical evaluation. Until such data exist, dihexa is best described as an investigational research compound rather than a proven intervention.
The proposed mechanism for dihexa centers on hepatocyte growth factor, or HGF, and its receptor c-Met. HGF signaling is involved in cell growth, survival, and synapse formation. Dihexa has been described as an HGF mimetic or modulator in preclinical literature. Whether it binds c-Met directly, increases HGF availability, or acts through another route remains uncertain. This mechanistic uncertainty is a recurring theme in reviews of the compound, and no single molecular model has been confirmed across independent laboratories.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide analog | Derived from an angiotensin IV sequence. |
| Appearance | White to off-white powder | Typical for lyophilized research peptides. |
| Solubility | Soluble in dimethyl sulfoxide; sparingly in water | Exact aqueous solubility depends on salt form and purity. |
| Typical storage temperature | -20 °C or below | Desiccated and protected from light for long-term storage. |
| Common synonyms | Dihexa; N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide | Names vary in catalog listings. |
Regulatory and commercial contexts differ from clinical medicine. Dihexa is not approved as a drug by major agencies, and no published human trials establish its safety or efficacy. It is often sold as a research chemical labeled for laboratory use only. Suppliers may provide certificates of analysis, but purity and identity depend on the specific batch. Legal status varies by country and may treat such compounds as unapproved substances for human consumption.
Dihexa is a synthetic peptidomimetic derived from angiotensin IV, a naturally occurring peptide fragment. It was created as a research compound to explore central nervous system signaling rather than as an approved therapeutic. Early work described it as a small, orally available molecule in rodent studies. Its structure combines tyrosine, isoleucine, and aminohexanoic acid components with a hexanoic acid cap. The compound is commonly referred to by the research code PNB-0408.
Development of dihexa followed from studies on angiotensin IV analogs and their effects on learning and memory. Researchers sought compounds with improved metabolic stability and brain penetration compared with natural peptides. In preclinical reports, dihexa was associated with changes in synaptic connectivity and performance on spatial tasks. These findings generated interest in its potential as a cognitive research tool. The work remains largely preclinical, and independent replication has been limited.
Identity and purity of dihexa samples are typically assessed with high-performance liquid chromatography and mass spectrometry. These methods can confirm molecular mass and estimate the presence of impurities. However, a certificate of analysis from a supplier is not a guarantee of independent testing. Researchers often require in-house verification before using a peptide in experiments. For solid samples, appearance, solubility, and chromatographic profile provide additional checks. Nuclear magnetic resonance may be used for structural confirmation when available.
Dihexa is commonly handled as a lyophilized powder in laboratory settings. Storage at -20 °C in a desiccated, light-protected container is typical for peptides. Repeated freeze-thaw cycles can degrade the material, so aliquoting is often recommended. Aqueous solutions may be less stable than organic stocks and should be prepared fresh when possible. Personnel should follow institutional safety procedures and avoid uncontrolled exposure. Because human effects are not well characterized, handling precautions are prudent.
=== Pharmacokinetics === Penicillin has low protein binding in plasma. The bioavailability of penicillin depends on the type: penicillin G has low bioavailability, below 30%, whereas penicillin V has higher bioavailability, between 60 and 70%. Penicillin has a short half-life and is excreted via the kidneys. This means it must be dosed at least four times a day to maintain adequate levels of penicillin in the blood. Early manuals on the use of penicillin, therefore, recommended injections of penicillin as frequently as every three hours, and dosing penicillin has been described as being similar to trying to fill a bath with the plug out. This is no longer required since much larger doses of penicillin are cheaply and easily available; however, some authorities recommend the use of continuous penicillin infusions for this reason.
Sometime prior to the series, he intended to use his Gyutanium Crystal to power a dangerous weapon, but was arrested. After escaping with help from his underling Zortac, Don Sanoa takes Tetsu and Kruger hostage and equips himself with Muscle Gear, but is deleted by the primary Dekarangers in their S.W.A.T. modes. Don Sanoa is voiced by Sōichirō Tanaka (田中 総一郎, Tanaka Sōichirō). Pyrian Kurachek (パイロウ星人コラチェク, Pairō Seijin Koracheku): A fire-themed serial arsonist from Planet Pyr who is charged with 4,103 counts of arson and three counts of planetary incineration and wears a heater-themed protective suit to move freely on other planets. He initially overpowers the Dekarangers until Deka Break discovers his weakness and defeats him. Using a giant version of his original suit he bought from Agent Abrella called a Flame Gear (フレイムギア, Fureimu Gia), Kurachek enlarges himself, but his new suit is deleted by the Deka Wing Cannon, causing his exposed body to be extinguished by the vacuum of space. Kurachek is voiced by Bin Shimada (島田 敏, Shimada Bin).
=== Marketing === Liraglutide was approved by the US Food and Drug Administration (FDA) in 2014, and by the European Medicines Agency (EMA) in 2015, for adults with a body mass index (BMI) of 30 or greater (obesity) or a BMI of 27 or greater (overweight) who have at least one weight-related condition. Liraglutide was approved by the FDA in 2019, for treatment of children aged ten years of age or older with type 2 diabetes, making it the first non-insulin drug approved to treat type 2 diabetes in children since metformin was approved in 2000. Novo Nordisk made deals with generic manufacturers to enter the United States market in 2024. The FDA approved the first generic liraglutide in December 2024, and granted the approval to Hikma Pharmaceuticals USA
==== Excretion ==== The plasma half-life of HB in man is estimated at 222±54 min. The clearance of HB differs between the two enantiomers and the age of the human subject. The clearance of the R(-) enantiomer is almost 10-fold greater than the clearance of the S(+) enantiomer. Clearance on average in elderly people, compared to young subjects, is slower. Excretion is mainly via urine, for the three major metabolites. The cyclohexenone glutathione adduct is excreted in the bile.
Sources: en.wikipedia.org
Directing edits to correct mutated sequences was first proposed and demonstrated in 1995. This initial work used synthetic RNA antisense oligonucleotides complementary to a pre-mature stop codon mutation in a dystrophin sequence to activate A-to-I editing of the stop codon to a read through codon in a model xenopus cell system. While this also led to nearby inadvertent A-to-I transitions, A to I (read as G) transitions can correct all three stop codons, but cannot create a stop codon. Therefore, the changes led >25% correction of the targeted stop codon with read through to a downstream luciferase reporter sequence. Follow on work by Rosenthal achieved editing of mutated mRNA sequence in mammalian cell culture by directing an oligonucleotide linked to a cytidine deaminase to correct a mutated cystic fibrosis sequence. More recently, CRISPR-Cas13 fused to deaminases has been employed to direct mRNA editing. In 2022, therapeutic RNA editing for Cas7-11 was reported. It enables sufficiently targeted cuts and an early version of it was used for in vitro editing in 2021.
On December 4, 2012, Cantrell confirmed that the new album had been completed. The first single, "Hollow", debuted online on December 18, available for digital download in January 2013, along with an official music video. On February 13, 2013, Alice in Chains posted on Facebook that their new album title would be an anagram of the letters H V L E N T P S U S D A H I E E O E D T I U R R. The next day they announced that the album would be called The Devil Put Dinosaurs Here, which was released on May 28, 2013, and debuted at No. 2 on the Billboard 200. To promote the album, Alice in Chains teamed up with Funny or Die for an 11-minute mockumentary titled AIC 23, in which Film Studies professor Alan Poole McLard (played by W. Earl Brown) attempts to make a documentary on Alice in Chains without any help from the actual band, interviewing other musicians instead. Among them are country singer Donnie 'Skeeter' Dollarhide Jr. (played by Jerry Cantrell), Reggae singer Nesta Cleveland (played by William DuVall), Black Metal musician Unta Gleeben Glabben Globben Globin (played by Mike Inez) and the hipster Stanley Eisen (played by Sean Kinney). The video was released on April 3, 2013, and also features cameos by Ann and Nancy Wilson from Heart, Mike McCready from Pearl Jam, Kim Thayil from Soundgarden, Duff McKagan from Guns N' Roses, Brent Hinds and Bill Kelliher from Mastodon, and Lars Ulrich and Robert Trujillo from Metallica.
=== 1970s === The scientific and medical markets have always been important for Edwards. The introduction of X-ray technology required the use of a vacuum. Vacuum technology also played an important role in the development of neuroimaging (brain scanners), like MRI, CT, and PET scanners. The first home computers were brought to the market in the 1970s and the development of computer technology has been unstoppable ever since. The mass production of CRT displays and integrated circuits necessitated electronic companies to scale up, with vacuum installations becoming bigger and demand for vacuum purity increasing. In the 1970s, Edwards Vacuum also collaborated with Seiko Seiki for the invention of magnetically suspended turbopumps. These molecular turbopumps use magnetically levitated bearings, which eliminate the risk of vacuum contamination, require less maintenance, and feature lower noise and vibration levels. This type of technology is particularly suitable for scientific applications and the harsh processes in semiconductor manufacturing. The newly emerged dry pumps and turbomolecular pumps supported innovation in the scientific instrument markets over the next couple of decades. The scientific instrument market is now the second biggest market for Edwards Vacuum, after the semiconductor and electronics industry.
the side lengths a, b, and c; the semiperimeter s = a + b + c/2 (half the perimeter p); the angle measures A, B, and C of the angles of the vertices opposite the respective sides a, b, and c (with the vertices denoted with the same symbols as their angle measures); the values of trigonometric functions of the angles; the area T of the triangle; the medians ma, mb, and mc of the sides (each being the length of the line segment from the midpoint of the side to the opposite vertex); the altitudes ha, hb, and hc (each being the length of a segment perpendicular to one side and reaching from that side (or possibly the extension of that side) to the opposite vertex); the lengths of the internal angle bisectors ta, tb, and tc (each being a segment from a vertex to the opposite side and bisecting the vertex's angle); the perpendicular bisectors pa, pb, and pc of the sides (each being the length of a segment perpendicular to one side at its midpoint and reaching to one of the other sides); the lengths of line segments with an endpoint at an arbitrary point P in the plane (for example, the length of the segment from P to vertex A is denoted PA or AP); the inradius r (radius of the circle inscribed in the triangle, tangent to all three sides), the exradii ra, rb, and rc (each being the radius of an excircle tangent to side a, b, or c respectively and tangent to the extensions of the other two sides), and the circumradius R (radius of the circle circumscribed around the triangle and passing through all three vertices).
Although Fredrickson claims that her experimental results are still valid, these experimental results have also been questioned due to poor statistical methodology, and Alan Sokal has pointed out that "given [Fredrickson and Losada's] experimental design and method of data analysis, no data whatsoever could possibly give any evidence of any nonlinearity in the relationship between "flourishing" and the positivity ratio — much less evidence for a sharp discontinuity." Another study surveyed a U.S. sample of 3,032 adults, aged 25–74. Results showed 17.2 percent of adults were flourishing, while 56.6 percent were moderately mentally healthy. Some common characteristics of a flourishing adult included: educated, older, married and wealthy. The study findings suggest there is room for adults to improve as less than 20 percent of Americans are living a flourishing life. (Keyes, 2002). Benefits from living a flourishing life emerge from research on the effects of experiencing a high ratio of positive to negative affect. The studied benefits of positive affect are increased responsiveness, "broadened behavioral repertoires", increased instinct, and increased perception and imagination. In addition, the good feelings associated with flourishing result in improvements to immune system functioning, cardiovascular recovery, lessened effects of negative affect, and frontal brain asymmetry.
Sources: en.wikipedia.org
Tyrosine hydroxylase is a tetramer of four identical subunits (homotetramer). Each subunit consists of three domains. At the carboxyl terminal of the peptide chain there's a short alpha helix domain that allows tetramerization. The central ~300 amino acids make up a catalytic core, in which all the residues necessary for catalysis are located, along with a non-covalently bound iron atom. The iron is held in place by two histidine residues and one glutamate residue, making it a non-heme, non-iron-sulfur iron-containing enzyme. The amino terminal ~150 amino acids make up a regulatory domain, thought to control access of substrates to the active site. In humans there are thought to be four different versions of this regulatory domain, and thus four versions of the enzyme, depending on alternative splicing, though none of their structures have yet been properly determined. It has been suggested that this domain might be an intrinsically unstructured protein, which has no clearly defined tertiary structure, but so far no evidence has been presented supporting this claim. It has however been shown that the domain has a low occurrence of secondary structures, which doesn't weaken suspicions of it having a disordered overall structure. As for the tetramerization and catalytic domains their structure was found with rat tyrosine hydroxylase using X-ray crystallography. This has shown how its structure is very similar to that of phenylalanine hydroxylase and tryptophan hydroxylase; together the three make up a family of homologous aromatic amino acid hydroxylases.
John Ternus is chosen as Apple's next CEO, effective September 1, 2026. FBI Director Kash Patel sues The Atlantic in a $250 million defamation lawsuit over an article claiming that Patel is an alcoholic. April 21 Trump says that he extended the Iran truce to allow time for an Iranian proposal to be submitted at Pakistan's request. 2026 Virginia redistricting amendment: Voters in Virginia approve a redistricting referendum aimed at boosting Democrats' chance of winning seats in the upcoming midterms. The DOJ charges the Southern Poverty Law Center with defrauding donors with payments to white nationalist informants. April 22 – A chemical accident in Institute, West Virginia leaves two dead and 30 others injured. April 23 Trump orders the US Navy to destroy any Iranian boats laying mines in the Strait of Hormuz. Acting Attorney General Blanche reclassifies marijuana to a Schedule III drug. Warner Bros. Discovery shareholders approve Paramount Skydance's proposed acquisition of the company in a deal valued at $111 billion including debt, moving the merger a step closer to completion pending regulatory approval. A shooting at the Mall of Louisiana in Baton Rouge leaves five injured and one dead. April 24 – Trump fires all 24 members of the National Science Board, the body that oversees the National Science Foundation.
The pathway can be activated by a range of signals, including hormones, growth factors and components of the extracellular matrix (ECM). It is stimulated by binding of an extracellular ligand to a receptor tyrosine kinase (RTK) in the plasma membrane, causing receptor dimerization and cross-phosphorylation of tyrosine residues in the intracellular domains. The regulatory subunit p85 binds to phosphorylated tyrosine residues on the activated receptor via its Src homology 2 (SH2) domain. It then recruits the catalytic subunit p110 to form the fully active PI3K enzyme. Alternatively, adaptor molecule Grb2 binds to phospho-YXN motifs of the RTK and recruits p85 via Grb2-associated binding (GAB) scaffold protein. The p110 subunit can also be recruited independently of p85. For example, Grb2 can also bind the Ras-GEF Sos1, leading to activation of Ras. Ras-GTP then activates the p110 subunit of PI3K. Other adaptor molecules such as insulin receptor substrate (IRS) can also activate p110.
Transuranium elements do not occur in sizeable quantities in nature and are commonly synthesized via nuclear reactions conducted with nuclear reactors. For example, under irradiation with reactor neutrons, uranium-238 partially converts to plutonium-239:
Sources: en.wikipedia.org
Dihexa is a synthetic peptide-like compound studied in preclinical research. It is often described as an angiotensin IV analog, but it is not an approved medicine. Public information comes mainly from laboratory work and commercial listings.
No major regulatory agency has approved dihexa as a therapeutic product. Human safety and efficacy data are limited. Its sale as a research chemical does not constitute approval for medical use.
Some animal and cell studies report synaptic or cognitive effects, which has led to nootropic framing online. These findings are preliminary and have not been confirmed in robust human trials. The term nootropic is not a regulatory category.
Dihexa has been proposed to act through HGF and c-Met signaling. This pathway is linked to synapse formation and cellular growth. Direct binding and the precise molecular step remain uncertain.